No abstract

Primary solitary fibrous tumors of kidney are rare in clinical practice. In literature, only eleven reported cases originated from renal pelvis. We report a case of a 45 year old middle-aged woman who was the first report that a small number of heterosexual cells have been found in urine. Definite diagnosis of this disease still depends on pathological examination, If preoperative puncture or other pathological examination supports the diagnosis of SFTs, the preferred treatment plan for it is surgical resection.

BackgroundThe nerve-sparing (NS) effect of robot-assisted radical prostatectomy (RARP) on patients with a high-risk prostate cancer remains unclear. The objective of this study was to compare the urinary continence, erectile function and oncology outcomes of the nerve-sparing and non-nerve-sparing (NNS) group during RARP surgeries.MethodsWe systematically searched databases including PubMed, Embase, Cochrane Library and Web of Science to identify relevant studies published in English up to December 2022. Newcastle-Ottawa Scale (NOS) was used as a quality evaluation tool to evaluate the quality of the literature parameters involved, including urinary continence, erectile function and oncologic outcomes, which were compared using the Stata 15.1 software (StataSE, USA).ResultsA total of 8 cohort studies involving 2499 patients were included. A meta-analysis of results showed that the NS group was beneficial to the recovery of urinary continence (RR 0.46, 95%CI 0.22, 0.96; p=0.045<0.05) and erectile function (RR 0.32, 95%CI 0.16, 0.63; p=0.001<0.05) 12 months after surgeries, which showed a better oncological outcome (RR 1.31, 95%CI 1.01, 1.69; p=0.01<0.05).ConclusionsThe current study results indicate that intraoperative NS during RARP is beneficial to long-term postoperative functional recovery and tumor prognosis of patients with high-risk prostate cancers. Due to interstudy interferences, the results should be interpreted with caution.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier: CRD42022384647.

No abstract